Chlormethine (Caryolysine®), carmustin (Bicnu®);Chlorméthine (Caryolysine®), carmustine (Bicnu®)

Annales de Dermatologie et de Venereologie

Volumn 134, Issue 12, 2007, Pages 992-996

  Esteve E ^a   Grange, F ^b  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORMETHINE; ALKYLATING AGENT;

ARTICLE; BLOOD TOXICITY; CHEMOTHERAPY; CONSULTATION; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN; PHOTOTHERAPY; PRESCRIPTION; PSORIASIS; T CELL LYMPHOMA; TREATMENT INDICATION; SKIN TUMOR;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; HUMANS; MECHLORETHAMINE; SKIN NEOPLASMS;

EID: 38049123694     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(07)78264-9     Document Type: Article

References (17)

1. Vonderheid EC. Treatment planning in cutaneous T-cell lymphoma. Dermatologic Therapy 2003;16:276-82.
2. Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clin Dermatol 2004;22:197-208.
3. Bachelez H. Traitements locaux des lymphomes T cutanés. Ann Dermatol Venereol 2005;132:5S23-5S25.
4. Avril MF. La Caryolysine locale. Ann Dermatol Venereol 1987;114:133-41.
5. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of Mycosis Fungoides. Update of the Standford experience. Arch Dermatol 2003;139:165-73.
6. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-Cell lymphoma. Hematol Oncol Clin North Am 1995;9:1031-56.
7. Bachelez H, Bagot M, Beylot-Barry M, Claudy A, Grange F, Grob JJ, et al. Algorithme thérapeutique lymphomes T cutanés. Propositions du groupe d'experts. Ann Dermatol Venereol 2005;132:5S43-4.
8. Estève E, Bagot M, Joly P, Souteyrand P, Beylot-Barry M, Vaillant L, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-Cell lymphomas. Arch Dermatol 1999;135:1349-53.
9. Foulc P, Evrard V, Dalac S, Guillot B, Delaunay M, Verret JL, Dreno B. Evaluation of a 1-h exposure time to mechloretamine in patients undergoing topical treatment. Br J Dermatol 2002;147:926-30.
10. de Quatrebarbes J, Estève E, Bagot M, Bernard P, Beylot-Barry M, Delaunay M, et al. Treatment of early-stage Mycosis Fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids. Arch Dermatol 2005;141:1117-20.
11. Van Vloten WA, Cooijmans ACM, Poel J, Meulenbelt J. Concentrations of nitrogen mustard in the air during topical treatment of patients with Mycosis Fungoides. Br J Dermatol 1993;128:404-6.
12. Snell J, Lillquist DR, Lewis-Younger C, Wallace DO. Exposure at home to airborne concentrations of nitrogen mustard during topical application for the treatment of mycosis fungoides: a case study. Dermatology 2000;200:124-8.
13. Du Vivier A, Vonderhyeid EC, Van Scott EJ, Urbach F. Mycosis fungoides, nitrogen mustard and skin cancer. Br J Dermatol 1978;99:61-3.
14. Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990;22:802-10.
15. Thomson KF, Sheehan-Dare RA, Wilkinson SM. Allergic contact dermatitis from topical carmustine. Contact dermatitis 2000;42:112.
16. Levin VA, Zackheim HS, Liu J. Stability of carmustine for topical application. Arch Dermatol 1982;118:450-1.
17. Zackheim HS. Time to achieve clearing with topical carmustine. J Am Acad Dermatol 1993;29:129.